Media & Announcements
Polpharma strengthens it's position in CEE - Biofarm, the leader of the Romanian market, joins the Group.
Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe.
Group News
July 27, 2026

Polpharma Group’s R&D supports growth in key therapeutic areas.
Polpharma Group's research and development capabilities support growth across its key therapeutic areas and strengthen its product pipeline.
Group News
June 26, 2026

26th International Scientific Conference on Expert Education Programs.
Polpharma joins the 26th International Scientific Conference on Expert Education Programs (EPE2026), supporting expert-led pharmaceutical education.
Group News
June 1, 2026

Polish RNA Technology Platform
Polpharma opens Poland's only end-to-end RNA medicine development platform in Starogard Gdanski, a PLN 238.7m investment strengthening medicine security.
Science & Innovation
May 20, 2026
Press releases
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Science & Innovation
ZF Polpharma
February 12, 2026
Polpharma SA launches a project under the STEP initiative
Polpharma launches an NCBR-funded STEP project to build a platform for manufacturing ready-to-use oligonucleotide RNA medicines, worth nearly PLN 80 million.
People
Polpharma Group
October 24, 2025
Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President
Polpharma Group appoints Sebastian Szymanek as CEO; Markus Sieger steps down after ten years at the helm and continues as a Supervisory Board member.
Group News
Polpharma API
October 13, 2025
Polpharma Group's environmental responsibility
Polpharma Group targets 17% GHG emission reduction by 2025 and 5% production waste reduction through ISO 14001-compliant environmental management.
People
Polpharma Group
June 12, 2025
Markus Sieger takes the helm as President ad interim at Medicines for Europe
Polpharma Group CEO Markus Sieger takes over as President ad interim of Medicines for Europe, prioritising medicine access and off-patent manufacturing.
Group News
Polpharma Group
June 4, 2025
Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty
Polpharma Group joins European off-patent industry leaders urging the EU to speed up pharma reform, strengthen the Bolar exemption and secure medicine supply.
Latest stories
For the media
Media Kit
Logos, photography and the Group boilerplate.
ZIP file (112.28 kb) updated quarterly
Group factsheet
Revenue, footprint, pipeline, employment and history.
Pdf file (112.28 kb) updated quarterly
Press Contact
Logos, photography and the Group boilerplate.
press@polpharma.com
RESPONDS WITHIN ONE BUSINESS DAY



.avif)









.avif)
























.avif)
